Alejandro Vazquez, MD
Otolaryngology · Warwick, RINPI 1437463056
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,553 of the $10,393 with a category attached, or 63.1%. 31 manufacturers reported payments, led by Optinose US, Inc. at 47.3% of the total. Reporting peaked in 2021 at $4,838 and has fallen 77.3% since, to $1,098 in 2025. Among otolaryngology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $30.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$5K
- AstraZeneca$960
- GSK$770
- Regeneron Healthcare Solutions, Inc.$709
- Sanofi$397
- Intersect ENT, Inc.$361
- plus $2K from 25 others
What the payments were for
- Consulting fees$2,00019%
- Speaking & faculty fees$1,84018%
- Food & beverage$6,55363%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 80 | $4,916 |
| AstraZeneca | 47 | $960 |
| GSK | 46 | $770 |
| Regeneron Healthcare Solutions, Inc. | 27 | $709 |
| Sanofi | 15 | $397 |
| Intersect ENT, Inc. | 9 | $361 |
| Stryker | 6 | $260 |
| Pfizer | 18 | $223 |
| Acclarent, Inc | 4 | $175 |
| Biohaven Pharmaceuticals, Inc. | 18 | $169 |
| Boehringer Ingelheim | 2 | $155 |
| Novartis | 8 | $150 |
| Hikma Pharmaceuticals USA | 8 | $140 |
| AbbVie(2 entities) | 7 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $119 |
| Medtronic | 3 | $101 |
| Kaleo, Inc. | 5 | $86 |
| Inspire Medical Systems, Inc. | 3 | $67 |
| Smith+Nephew | 3 | $66 |
| Pharming Healthcare, Inc. | 3 | $60 |
| Alk-abello, Inc | 3 | $56 |
| Watermark Medical, Inc. | 3 | $53 |
| Aerin Medical Inc. | 3 | $46 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| Neurent Medical Limited | 2 | $39 |
| Mylan Pharmaceuticals Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Amgen | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Omeros Corporation | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,393 in reported general payments places this provider in the 90th percentile of 23 otolaryngology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 26 | $16,214 |
| Azelastine Hcl | 231 | $6,524 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 32 | $3,130 |
| Fluticasone Propionate | 145 | $3,027 |
| Ipratropium Bromide | 65 | $2,420 |
| Mometasone Furoate | 17 | $2,124 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $358 |
| Omeprazole | 14 | $170 |
| Doxycycline Monohydrate | 13 | $139 |
| Prednisone | 47 | $115 |
| Azithromycin | 12 | $75 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $46 |
| Cephalexin | 14 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $4,916 | $16,21426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 23 otolaryngology providers in Rhode Island.
Other otolaryngology in Warwick
- Mark AndreozziWarwick$15K
- Amit PatelWarwick$7K
- Barbara GuilletteWarwick$4K
- George JacewiczWarwick$0
- Frederick GodleyProvidence$96K
- David CameronWesterly$7K
- Jeffrey FeldmanWesterly$4K
- John TarroProvidence$4K
- Eugene StecWesterly$4K
- Prabhakar TipirneniWakefield$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.